ArticleScientific reports2025
Exploring the predictive values of ABSI and BRI in premature coronary artery disease based on a real world study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Exploring predictors of premature coronary artery disease (PCAD) based on a real-world study. We employed 50,190 individuals and collected their baseline characteristics, including medical history, anthropometric measurements, and blood biochemistry indicators from 2001 to 2018. PCAD were screened strictly based on diagnostic and exclusion criteria, and ultimately 14,469 individuals (including 387 in coronary angiography for the diagnosis of PCAD and 14082 in the control who thought that the degree of coronary stenosis did not meet diagnostic criteria) were included in analyzed. Propensity score matching (PSM) was used to assess these patients. We used multivariable Cox proportional hazards regression to identify risk factors and developed a nomogram to estimate the risk of major adverse cardiac events (MACE) over the 36-month follow-up period. Receiver operating characteristic (ROC) analysis was used to evaluate the diagnostic performance of the risk factors. All patients were followed up for 36 months，and a survival curve was plotted. Before PSM matching, PCAD patients exhibited significantly higher levels of several risk factors, including body mass index (BMI), waist circumference (WC), triglycerides (TG), hemoglobin A1c (HbA1c), glucose, and various cardiovascular indicators such as systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP), compared to the control group (P < 0.001). After PSM matching, only the body roundness index (BRI) remained significantly higher in PCAD patients (P < 0.001).In Cox regression analysis and nomogram development, gender, age, smoking, serum creatinine, aspartate aminotransferase (AST), ABSI, and BRI were identified as significant risk factors for PCAD (P < 0.01-0.05), both before and after PSM matching. The ROC curve analysis showed that combining ABSI and BRI improved diagnostic performance, with an area under the curve (AUC) of 0.73.Survival analysis revealed that high ABSI and BRI significantly predicted poorer prognosis in PCAD patients, regardless of PSM matching (P < 0.05). Further survival analysis combining ABSI and BRI demonstrated that, after PSM matching, high ABSI consistently indicated a worse prognosis, irrespective of BRI levels. ABSI and BRI are high-risk factors for PCAD, and ABSI combined with BRI with a higher diagnosis. High ABSI is associated with poor prognosis in PCAD patients, and the exact mechanism needs to be further explored.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.